Our differential expression analysis revealed that mRNAs of EGFR, mTOR, NOS2, TGFB1, FGFR1, and MAP2K1 were overexpressed in multiple cancer types compared to corresponding adjacent healthy cohorts, while the survival analysis revealed that cohorts with higher expressions of EGFR, MAP2K1, and NOS2 exhibited shorter OS than cohorts with low expression profiles. This evidence concerns the gene MTOR and cancer.